Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ODYSSEY: A Phase 2b Study of Suprachoroidally Administered CLS-AX in Participants With Neovascular Age-Related Macular Degeneration

NCT05891548 is registered in ClinicalTrials.gov with Clearside Biomedical, Inc. as lead sponsor.

NCT NCT05891548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05891548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ODYSSEY: A Phase 2b Study of Suprachoroidally Administered CLS-AX in Participants With Neovascular Age-Related Macular Degeneration
Lead sponsor
Clearside Biomedical, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2023
Completion date
August 20, 2024
Enrollment
60 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration